Search Results

​Laura Angelini

Laura Angelini is general manager, Renal Care. Angelini joined Baxter in 2016. Previously, she worked with Johnson & Johnson in roles of increasing responsibility over her 25-year tenure, including as vice president, Medical Devices & Diagnostics, Eastern Europe and most recently as president, North America & Global Franchise Development, Johnson & Johnson Vision Care.

Our Story

Baxter touches the lives of millions of people around the world every day. Our products and therapies can be found throughout hospitals and clinics – from the ER to the OR, from the pharmacy to the ICU – as well as advancing patients’ care in their homes.  

OLD Our History

​Innovation is at our core.  For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. 

Baxter Reports Third-Quarter 2023 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2023.

Baxter Reports Second-Quarter 2023 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023.

Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions. 

Baxter Publishes Annual Corporate Responsibility Report, Reinforcing Longstanding Commitment to Making a Meaningful Difference

Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its 2022 Corporate Responsibility Report.

Baxter Names Chris Toth CEO of Proposed Kidney Care Spinoff

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses. Until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by July 2024 or earlier, Mr.